UK – The NICE recommends Rinvoq for psoriatic arthritis patients

The chronic, inflammatory disease affects an estimated 24 in every 10,000 people.

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending Rinvoq (upadacitinib) 15mg as a new option for treating adults with active psoriatic arthritis (PsA).

This treatment is recommended for patients who have peripheral arthritis with three or more tender joints, and three or more swollen ligaments.

Upadacitinib is an oral, once daily selective and reversible janus kinase inhibitor (JAKi). This can be used as a monotherapy or in combination with methotrexate (MTX). The publication of the FAD means that eligible patients can now access the treatment via the NHS in England and Wales…